The HSE, Epilepsy Ireland, OACS Ireland, FACS Forum and Trinity College Dublin have come together to organise the first National Conference on The Consequences of Sodium Valproate (Epilim) in Trinity College on March 22nd 2019.
The full-day, free event is for patients & families affected by valproate exposure, healthcare professionals and policy makers and features a range of experts from the UK and Ireland in addition to the experiences of families affected and updates on the Irish response to the valproate problem to date.
Full details of the event are below and free tickets can be reserved at valproate.eventbrite.ie.
National Conference on
The consequences of Sodium Valproate (Epilim)
50 years on
Friday March 22nd 2019
9.30am – 5pm
Stanley Quek Theatre
Biomedical Sciences Institute | Trinity College Dublin
152-160 Pearse Street | Dublin 2
Sodium Valproate (Epilim) is a medication used to treat epilepsy and bipolar disorder. The European Medicines Agency has restricted its use in women due to the increased risk of disabilities in children exposed to Valproate in the womb (Foetal Valproate Syndrome).
This conference will address the key issues today facing families, healthcare professionals and policy makers in:
- The pharmacology of sodium valproate
- Sodium valproate: Who knew what and when?
- Reducing the risks associated with sodium valproate
- Diagnosing and managing foetal valproate syndrome
- Living with foetal valproate syndrome and the consequences of sodium valproate
- The Irish Health Service’s response to the valproate problem
- Dr Colm Henry, HSE Chief Clinical Officer
- Karen Keely, Chairperson, OACS Ireland
- Dr Jeff Aronson, Clinical Pharmacologist, Centre for Evidence-Based Medicine, Oxford
- Prof. Carl Heneghan, , Oxford
- Prof. Amanda Wood, Professor of Developmental Neuropsychology, Aston University, Birmingham
- Dr Peter Turnpenny, Clinical Geneticist, Royal Devon & Exeter Hospital, UK
- Prof. Andrew Green, Consultant Clinical Geneticist, Our Lady's Children's Hospital, Crumlin
- Families affected by Foetal Valproate Syndrome
- Members of the HSE’s Valproate Response project team
Book your place free of charge at:
For further information, please contact:
Sabrina Doyle, HSE: 01 6352508 | email@example.com